39 results about "Ketotifen" patented technology

Compositions, formulations, methods, and systems for treating regional fat deposits comprise contacting a targeted fat deposit with a composition comprising long acting beta-2 adrenergic receptor agonist and a compound that reduces desensitization of the target tissue to the long acting beta-2 adrenergic receptor agonist, for example, glucocorticosteroids and / or ketotifen. Embodiments of the composition are administered, for example, by injection, and / or transdermally.

The invention relates to an H1-receptor-antagonist-containing inhalation preparation which contains an H1 receptor antagonist and one or more pharmaceutical auxiliary materials suitable for inhalation administration. The H1 receptor antagonist is one or more of loratadine, desloratadine, cetirizine, levocetirizine, astemizole, ketotifen, ebastine, fexofenadine, avastin, mequitazine, mizolastine and salts thereof, and preferably one or more of loratadine, desloratadine, cetirizine, levocetirizine, ebastine, mizolastine, avastin, mequitazine, ketotifen and hydrochlorides or fumarates thereof.

Ophthalmic compositions comprising ketotifen and a source of hydrogen peroxide providing an amount of hydrogen peroxide of from about 0.001 to about 0.1% (w / v) of hydrogen peroxide, and methods for the treatment and prevention of allergic conjunctivitis using these compositions are provided herein.

The present invention provides a method of inhibiting dependence to an opioid by a human subject in need thereof. The method comprises administering an effective amount of a pharmaceutical composition to the subject during opioid therapy. The pharmaceutical composition comprises a) a non-steroidal anti-inflammatory drug (NSAID); and b) a co-agent selected from the group consisting of: fexofenadine, ketotifen, desloratadine, cetirizine, salts thereof and combinations thereof.

The present invention provides a method of inhibiting tolerance to an opioid by a human subject in need thereof. The method comprises administering an effective amount of a pharmaceutical composition to the subject during opioid therapy. The pharmaceutical composition comprises a) a non-steroidal anti-inflammatory drug (NSAID); and b) a co-agent selected from the group consisting of: fexofenadine, ketotifen, desloratadine, cetirizine, salts thereof and combinations thereof.

The invention relates to methods of inhibiting side effects associated with vaccination in a human subject in need thereof. The method comprises administering an effective amount of a pharmaceutical composition to the subject before the subject is vaccinated, wherein the pharmaceutical composition comprises: a) a non-steroidal anti-inflammatory drug (NSAID); and b) a co-agent selected from the group consisting of: fexofenadine, ketotifen, desloratadine and cetirizine and combinations thereof.

The invention discloses allergy-removal rhinitis cream which is prepared from, by weight, 8-10% of astragalus membranaceus, 8-10% of codonopsis pilosula, 10-15% of scutellaria baicalensis, 3-5% of lumbricus, 3-5% of as arum, 3-5% of honeysuckle, 3-5% of menthol, 3-5% of radix aconiti carmichaeli and the balance finished product western medicine supplementary materials; the finished product western medicine supplementary materials comprise ketotifen, cyproheptadine, prednisone, chlortrimeton and magnesium sulfate; the traditional Chinese medicine is crushed and ground in proportion, the western medicine supplementary materials are crushed and ground in proportion, the traditional Chinese medicine ingredients and the western medicine supplementary materials are stirred and mixed, polyving akohol, sodium methyl cellulose and glycerinum are added and blended into a paste shape, and the allergy-removal rhinitis cream is obtained. The Chinese herbal medicine has the effects of clearing away heat and dispelling wind-evil, dispelling cold to dredge main and collateral channels, tonifying the lungs and the spleen, and nourishing the kidney and supplementing the yang; the finished product western medicine supplementary materials have the functions of inhibiting exudation of inflammation, lowering the permeability of blood capillary, resisting to histamine, acetyl choline and 5-hydroxytryptamine are achieved, cytomembranes of mast cells can be stabilized, and releasing of anaphylactic mediators is inhibited.

The present invention provides a method of inhibiting tolerance to an opioid by a human subject in need thereof. The method comprises administering an effective amount of a pharmaceutical composition to the subject during opioid therapy. The pharmaceutical composition comprises a) a non-steroidal anti-inflammatory drug (NSAID); and b) a co-agent selected from the group consisting of: fexofenadine, ketotifen, desloratadine, cetirizine, salts thereof and combinations thereof.

The present invention is a method of treating enteropathic arthritis in a human subject in need thereof. The method comprises administering an effective amount of a pharmaceutical composition to the subject, wherein the pharmaceutical composition comprises: a) a non-steroidal anti-inflammatory drug (NSAID), and / or a salt thereof; and b) a co-agent selected from the group consisting of: fexofenadine, ketotifen, desloratadine, cetirizine, salts thereof and combinations thereof.

Ophthalmic compositions comprising ketotifen and a source of hydrogen peroxide providing an amount of hydrogen peroxide of from about 0.001 to about 0.1% (w / v) of hydrogen peroxide, and methods for the treatment and prevention of allergic conjunctivitis using these compositions are provided herein.

Ophthalmic compositions comprising ketotifen, a source of hydrogen peroxide providing an amount of hydrogen peroxide of from about 0.001 to about 0.1% (w / v), one or more ocular-compatible hydrogen peroxide stabilizers, HPMC and CMC, and methods for the treatment and prevention of allergic conjunctivitis using these ophthalmic compositions are provided herein.

The invention relates to methods of inhibiting side effects associated with vaccination in a human subject in need thereof. The method comprises administering an effective amount of a pharmaceutical composition to the subject before the subject is vaccinated, wherein the pharmaceutical composition comprises: a) a non-steroidal anti-inflammatory drug (NSAID); and b) a co-agent selected from the group consisting of: fexofenadine, ketotifen, desloratadine and cetirizine and combinations thereof.

The invention relates to a fluticasone and fluticasone ester / H1 receptor antagonist inhalant which contains fluticasone and fluticasone ester and one or more H1 receptor antagonists used as active components, and one or more pharmaceutical auxiliary materials suitable for inhalation administration. The H1 receptor antagonist is one or more of loratadine, desloratadine, cetirizine, levocetirizine, astemizole, ketotifen, ebastine, fexofenadine, avastin, mequitazine, mizolastine and salts thereof, and preferably one or more of loratadine, desloratadine, cetirizine, levocetirizine, ebastine, mizolastine, avastin, mequitazine, ketotifen and hydrochlorides or fumarates thereof.

The invention relates to a special-effect drug for treating asthma, which is composed of a drug I, a drug II and a drug III; the drug I comprises the following components by weight: 0.016g of dead bacillus calmette guerin vaccine, 1.071g of potato starch, 0.3g of aminophylline, 0.001g of ketotifen, 0.005g of dioxopromethazine, 0.025g of levomisole, 0.03g of bromhexine and 0.8g of green tea; the drug II comprises the following components by weight: 1.4g of fructus schisandrae, 1.4g of astragalus and 0.3g of cinnamon; and the drug IIT comprises the following components by weight: 1.2g of radix codonopsis, 1.2g of astragalus, 0.3g of epimedium and 0.4g of gypsum. The special-effect drug disclosed by the invention is prepared on the basis of combination of Chinese and western medicine sciences, has remarkable treatment effect, and treats both symptoms and root causes.

The invention relates to the technical field of neurology, in particular to a medicine for treating neurasthenia, which comprises the following components (by mass percentage): trimetazine: 2-4%, midecamycin: 1-5%, teabutemetone : 30-40%, Taurine: 15-17%, Ketotifen: 2-6%, Catechin: 23-25%, Niacinamide: 3-5%, Oleanolic acid: 1-3% , Quetiapine: 1.5-2.5%, Loxoprofen: 2.5-11.5%. The invention also discloses a preparation method of the drug, which includes the following steps: step 1: preparing materials, step 2: drying and grinding into powder, step 3: pulverizing, step 4: preparing ethanol solution, step 5: concentrating and drying, and step 6 : extract medicine. The invention can effectively improve body function and immunity, has significant curative effect on treating neurasthenia, has no toxic and side effects on human body, can relieve anxiety and cognitive deficiency symptoms, and has the effects of clearing away heat and fire, regulating qi and dredging collaterals.

The invention discloses a Western medicine composition for treating sciatica and application thereof. Active ingredients of the Western medicine composition consist of the following components in parts by mass: 42-49 parts of nabumetone, 13-18 parts of taurine and 9-15 parts of ketotifen. The dosage for adults is 1.1-1.3 mg of active ingredients / kg / day. The medicine composition provided by the invention takes the nabumetone, the taurine and the ketotifen as raw materials, has great therapeutic effect on the sciatica, and has an effective rate up to 96% and a total effective rate of 100% which are verified by clinic treatments; moreover, no relapse occurs after patients are recovered; the composition is safe without toxic or side effects.